Sep 27 |
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Could Be Less Than A Year Away From Profitability
|
Sep 24 |
Aurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus Nephritis
|
Sep 19 |
Aurinia Pharmaceuticals: LUPKYNIS Leading The Way In Lupus Nephritis Treatment
|
Sep 18 |
Aurinia Pharmaceuticals: This Recovery Can Continue
|
Sep 13 |
Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Conference
|
Sep 13 |
Aurinia Pharmaceuticals shares gain as co reports Board restructuring
|
Sep 12 |
Aurinia Announces Board Restructuring
|
Sep 6 |
Top High Growth Tech Stocks To Watch In September 2024
|
Sep 6 |
Aurinia doses first subject in Phase Ia trial of AUR200 for autoimmune diseases
|
Sep 5 |
Aurinia Announces First Participant Dosed in AUR200 Single Ascending Dose Trial
|